-- 1 of 28 -- st April 14, 2026 -- 2 of 28 -- Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary note on Non-GAAP financial measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website. 3 -- 3 of 28 -- IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc.; bleximenib R&D co-funding agreement with Blackstone Life Sciences Oncology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; ICOTYDE was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications; JNJ-4804 R&D co-funding agreement with Royalty Pharma plc Immunology INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Neuroscience PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK., INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc.; UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Other Strategic partnerships, collaborations & licensing arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: 4 -- 4 of 28 -- CEO Remarks Sales performance and earnings review Capital allocation and guidance update Q&A Agenda 5 John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Darren Snellgrove Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech 1 2 3 4 -- 5 of 28 -- Joaquin Duato Chairman and Chief Executive Officer -- 6 of 28 -- 7 Q1 Earnings Summary operational sales growth1,2 Six key businesses driving growth 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (540) basis point headwind from STELARA -- 7 of 28 -- Innovative Medicine: 7.4% operational sales growth1,2 8 Oncology Neuroscience Immunology 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (920) basis point headwind from STELARA Note: Includes existing products and planned future launches -- 8 of 28 -- 9 ICOTYDE U.S. FDA approval brings new option for first-line systemic treatment of plaque psoriasis Preferred first line systemic treatment for patients 12 and older with moderate to severe plaque psoriasis No mandatory TB test or lab monitoring Full launch occurred immediately on approval Potential to revolutionize how psoriatic disease is treated First and only IL-23R targeted oral peptide to deliver complete skin clearance and favorable safety profile in a once-daily pill Immunology -- 9 of 28 -- Innovative Medicine: 7.4% operational sales growth1,2 10 Oncology Neuroscience Immunology 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (920) basis point headwind from STELARA Note: Includes existing products and planned future launches -- 10 of 28 -- MedTech: 4.6% operational sales growth1 11 Cardiovascular Surgery Vision VARIPULSE Platform Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Shockwave Intravascular Lithotripsy System OMNYPULSE Catheter Impella® Heart Pump Technology OTTAVA Robotic Surgical System ETHICON 4000 Surgical Stapler ACUVUE® OASYS 1-Day Family TECNIS Odyssey TECNIS PureSee MONARCH Platform 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Includes existing products and planned future launches -- 11 of 28 -- 12 Note: related to sales; excludes the impact of translational currency -- 12 of 28 -- Darren Snellgrove Vice President, Investor Relations -- 13 of 28 -- % Change Q1 2025 Q1 2026 Regional sales results Operational1 Reported 8.3% 8.3% $12.3 $13.3 U.S. 2.7 14.5 5.1 5.8 Europe 2.5 10.8 1.2 1.3 Western Hemisphere (ex U.S.) 6.1 8.5 3.3 3.6 Asia-Pacific, Africa 3.9 11.9 9.6 10.7 International 6.4% 9.9% $21.9 $24.1 Worldwide (WW) Dollars in billions 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 1st Quarter 2026 sales 14 -- 14 of 28 -- $24.1 $21.9 $6.6 $6.7 (2.5)%; (7.2)%1 $2.70 $2.77 Dollars in billions, except EPS Reported %; Operational %1 Sales Adjusted earnings2 Adjusted EPS2 9.9%; 6.4%1 GAAP earnings (1.4)% Q1 2026 Q1 2025 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 1st Quarter 2026 financial highlights GAAP EPS 15 Q1 2026 Q1 2025 Q1 2026 Q1 2025 Q1 2026 Q1 2025 Q1 2026 Q1 2025 (52.4)% (52.9)% $5.2 $11.0 $2.14 $4.54 -- 15 of 28 -- Other $2,899 Neuroscience $2,175 Oncology $6,973 Immunology $3,380 ■ Reported growth ■ Operational growth1 $15,426 11.2%, 7.4% WW sales $MM Key drivers of operational performance1 • DARZALEX increase primarily driven by strong share gains and market growth, partially offset by inventory dynamics • CARVYKTI increase driven by share gains and continued site expansion • TECVAYLI growth driven by launch uptake and share gains from expansion in the community setting and recent U.S. TECVAYLI + DARZALEX FASPRO approval • TALVEY growth driven by share gains from expansion in the community setting • RYBREVANT/LAZCLUZE growth driven by launch uptake and share gains • ERLEADA increase driven by continued share gains in mCSPC and market growth • IMBRUVICA decrease driven by share loss due to continued competitive pressure and unfavorable patient mix Oncology • TREMFYA growth due to share gains across all indications with significant IBD launch momentum and market growth • SIMPONI/SIMPONI ARIA and REMICADE decrease driven by share loss, biosimilar competition, and unfavorable patient mix, partially offset by market growth • STELARA decline driven by the impact of biosimilar competition, increasing adoption of novel classes, and unfavorable patient mix Immunology • SPRAVATO growth driven by continued increased physician and patient demand • CAPLYTA driven by strong continued momentum in the aMDD launch • INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA increase primarily driven by favorable patient mix Neuroscience • UPTRAVI increase driven by market and share growth, partially offset by inventory dynamics • OPSUMIT/OPSYNVI growth driven by share gains, market growth, and favorable patient mix • PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA increase driven by favorable patient mix • XARELTO decrease driven by continued share erosion Other Adjusted operational sales2: WW: 5.6%, U.S. 6.3%, Int’l 4.5% Innovative Medicine highlights – 1st quarter 2026 WW 11.2%, U.S. 9.6%, Int’l 13.4% Reported: WW 7.4%, U.S. 9.6%, Int’l 4.3% Operational1: (8.8)%, (11.8)% 22.8%, 17.8% 2.1%, (0.9)% Strong operational growth1 of 7.4% driven primarily by Oncology and Neuroscience 32.0%, 29.3% 16 Stelara impacted results1 by ~(920) basis points 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded -- 16 of 28 -- Key drivers of operational performance1 • Electrophysiology: Increase driven by procedure growth, commercial execution, new product performance (VARIPULSE, TRUPULSE, NUVISION and CRYSTAL), and OUS inventory dynamics, partially offset by competitive pressures in PFA • Abiomed: Double digit growth driven by continued strong adoption of Impella 5.5 and Impella CP • Shockwave: Double digit growth driven by strong adoption of Coronary and Peripheral portfolios and new product launches (JAVELIN & E8) Cardiovascular • Advanced: • Biosurgery: ~ +5% growth driven by continued strength of the portfolio and commercial execution, partially offset by the impact of the surgery transformation program and VBP in China • Endocutters: ~ -3% due to competitive pressures and VBP in China • Energy: ~ +2% increase driven by new product launches, partially offset by VBP in China • General: Increase primarily due to technology penetration and upgrades within our differentiated Wound Closure portfolio (Barbed & PLUS Sutures) and market expansion, offset by OUS tender timing Surgery • Contact Lenses/Other: Increase driven by strong performance of the ACUVUE OASYS 1-Day family of products and strategic price actions, partially offset by inventory dynamics OUS • Surgical: Growth driven by strength of recent product innovations, robust demand for premium IOLs, and strong commercial execution, partially offset by competitive pressures in the U.S. Vision Growth across all platforms primarily driven by new product launches and strong commercial execution: • Hips: Increase driven by new product launches (EMPHASYS) • Knees: Increase driven by strength of the ATTUNE portfolio, in part driven by pull through related to the VELYS Robotic assisted solutions • Trauma: Growth driven by recently launched products (VOLT) • Spine, Sports & Other: New product innovations (TriAltis) and growth in shoulders, offset by competitive pressures and inventory dynamics Orthopaedics Adjusted operational sales2: WW 4.7%, U.S. 6.1%, Int’l 3.2% Surgery $2,511 Orthopaedics $2,383 Vision $1,365 Cardiovascular $2,377 ■ Reported growth ■ Operational growth1 $8,636 7.7%, 4.6% WW sales $MM Solid operational growth1 of 4.6% due to commercial execution and innovation WW 7.7%, U.S. 5.9%, Int’l 9.7% Reported: WW 4.6%, U.S. 5.9%, Int’l 3.2% Operational1: 13.0%, 10.5% 6.7%, 3.6% 4.8%, 1.2% 6.3%, 3.2% MedTech highlights – 1st quarter 2026 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 17 -- 17 of 28 -- % Increase (Decrease) 2025 2026 % to Sales Amount % to Sales Amount 9.9 100.0 $21,893 100.0 $24,062 Sales to customers 10.2 33.6 7,357 33.7 8,106 Cost of products sold 9.8 66.4 14,536 66.3 15,956 Gross Profit 18.0 23.3 5,112 25.1 6,034 Selling, marketing and administrative expenses 9.4 14.7 3,225 14.7 3,527 Research and development expense - - 0.1 36 In-process research and development impairments (0.6) (128) 0.2 43 Interest (income) expense, net (33.4) (7,321) 1.2 294 Other (income) expense, net 0.1 17 0.1 32 Restructuring (56.1) 62.3 13,631 24.9 5,990 Earnings before provision for taxes on income (71.3) 12.1 2,632 3.1 755 Provision for taxes on income (52.4) 50.2 $10,999 21.8 $5,235 Net Earnings (52.9) $4.54 $2.14 Net earnings per share (Diluted) 2,423.8 2,445.2 Average shares outstanding (Diluted) 19.3% 12.6% Effective tax rate Adjusted earnings before provision for taxes and net earnings1 (2.4) 36.6 $8,011 32.5 $7,821 Earnings before provision for taxes on income (1.4) 30.6 $6,706 27.5 $6,614 Net earnings (2.5) $2.77 $2.70 Net earnings per share (Diluted) 16.3% 15.4% Effective tax rate 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website (Unaudited; Dollar and shares in millions except per share figures) 18 1st Quarter 2026 Condensed consolidated statement of earnings -- 18 of 28 -- % Increase (Decrease) 2025 2026 Innovative Medicine % to Sales Amount % to Sales Amount 11.2 100.0 $13,873 100.0 $15,426 Sales to customers 7.3 24.3 3,371 23.4 3,617 Cost of products sold 12.4 75.7 10,502 76.6 $11,809 Gross Profit 29.1 16.3 2,261 18.9 2,918 Selling, marketing and administrative expenses 10.4 18.4 2,548 18.2 2,813 Research and development expense (1.5) (204) (0.2) (43) Other segment items 1 3.8 42.5 5,897 39.7 $6,121 Adjusted segment income before tax 2 (Unaudited; Dollar in millions) Adjusted earnings before provision for taxes on income by segment 19 % Increase (Decrease) 2025 2026 MedTech % to Sales Amount % to Sales Amount 7.7 100.0 8,020 100.0 $8,636 Sales to customers 14.2 34.8 2,795 37.0 3,192 Cost of products sold 4.2 65.2 5,225 63.0 $5,444 Gross Profit 9.4 33.1 2,656 33.6 2,906 Selling, marketing and administrative expenses 6.4 8.4 671 8.3 714 Research and development expense (2.2) (182) (1.2) (98) Other segment items 1 (7.6) 25.9 2,080 22.3 $1,922 Adjusted segment income before tax 2 % Increase (Decrease) 2025 2026 Enterprise % to Sales Amount % to Sales Amount (2.4) 36.6 $8,011 32.5 $7,821 Adjusted income before tax 2 1st Quarter 2026 1 Includes other Income and Expense 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website -- 19 of 28 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 20 of 28 -- Capital allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases Higher priority Lower priority Investment in M&A Q1 2026 Dollars in billions $22.1 Cash and marketable securities ($55.0) Debt ($32.9) Net debt ~$1.5 Free cash flow1,2 Q1 2026: $3.5B invested in R&D $3.1B in dividends paid to shareholders Note: Values may be rounded 1 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment 2 Estimated as of April 14, 2026. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings Note: Values may be rounded Capital allocation strategy 21 -- 21 of 28 -- Operational2 sales guidance of 6.4% and adjusted operational EPS2,4 at 5.7% (midpoints) Comments January 2026 April 2026 Increasing midpoint to 6.1% 5.4% - 6.4% 5.6% - 6.6% Adjusted operational sales1,2 Increasing midpoint by $0.2B to 6.4% $99.5B - $100.5B 5.7% - 6.7% $99.7B - $100.7B 5.9% - 6.9% Operational sales2 Increasing midpoint by $0.3B to 7.0% Incremental FX impact of $0.1B or 0.1% $100.0B - $101.0B 6.2% - 7.2% $100.3B - $101.3B 6.5% - 7.5% Estimated reported sales 3 Maintaining Increase of at least 50 bps Increase of at least 50 bps Adjusted pre-tax operating margin4,5 Maintaining $1.0 - $1.2 billion $1.0 - $1.2 billion Net other income4 Maintaining $300 - $400 million $300 - $400 million Net interest expense / (income) Maintaining 17.5% - 18.5% 17.5% - 18.5% Effective tax rate4 Increasing midpoint by $0.02 to 5.7% $11.28 - $11.48 4.5% - 6.5% $11.30 - $11.50 4.7% - 6.7% Adjusted EPS (operational)2,4 Increasing midpoint by $0.02 to 7.1% Maintaining FX impact of $0.15 or 1.4% $11.43 - $11.63 5.9% - 7.9% $11.45 - $11.65 6.1% - 8.1% Adjusted EPS (reported)3,4 2026 P&L guidance 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Calculated using Euro Average Rate: April 2026 = $1.17 and January 2026 = $ 1.17 Note: Values may be rounded 22 -- 22 of 28 -- Innovative Medicine • Expect more pronounced impact from newly launched products as the year progresses • Anticipate generic competition for OPSUMIT (second half in U.S.) and SIMPONI (first half in EU; potentially second half in U.S.) • Expect impact of voluntary agreement with the U.S. government to be evenly distributed throughout the year • Expect continued acceleration of newly launched products as the year progresses with normalized seasonality • Surgery Transformation sales headwinds expected to increase through the year • Anticipate additional rounds of VBP in China throughout the year, heavier in the second half of the year Phasing Considerations MedTech • Expect heavier investment in the first half of the year • Intra-Cellular benefit laps in Q2 • Anticipate higher earnings per share growth in the second half of the year compared to the first half P&L 23 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Anticipate fairly consistent operational1 sales growth in the first and second half; 53rd week impacts the second half -- 23 of 28 -- Innovative Medicine Anticipated 2026 milestones1 driving long-term value creation MedTech 24 ICOTYDE in PsO TECVAYLI + DARZALEX in RRMM TREMFYA in PsA SD TECVAYLI in RRMM INLEXZO in HR NMIBC nipocalimab in WAIHA and SLE CAPLYTA in bipolar mania JNJ-4804 ERLEADA in LPC & HRPC OTTAVA ETHIZIA STSF Dual Energy Catheter C2 Aero Catheters TECNIS PureSee IOL ATTUNE Hinge VOLT MONARCH Urology VARIPULSE Pro 1 List above is not inclusive of all 2026 anticipated milestones across approvals, planned submissions, potential clinical data presentations, and launches PsO: Psoriasis; RRMM: Relapsed/refractory multiple myeloma; PsA SD: Psoriatic arthritis structural damage; HR NMIBC: High-risk non-muscle invasive bladder cancer; WAIHA: Warm autoimmune hemolytic anemia; SLE: Systemic lupus erythematosus; LPC: Localized prostate cancer; HRPC: High-risk prostate cancer; STSF: SMARTTOUCH Surround Flow; IOL: Intraocular lens -- 24 of 28 -- Save the Date 25 Enterprise Business Review Save the Date Tuesday, December 8, 2026 Innovative Medicine MedTech Surgery Vision Cardiovascular Oncology Neuroscience Immunology -- 25 of 28 -- Q&A John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Darren Snellgrove Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech -- 26 of 28 -- Slide footer goes here if required 27 -- 27 of 28 -- POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA PRESENTATIONS¹ Phase III Phase I/ II US TREMFYA (guselkumab) P US nipocalimab US ERLEADA (apalutamide) P ICOTYDE (icotrokinra) ERLEADA (apalutamide) JNJ-4804 Co-antibody Therapy Psoriatic Arthritis Structural Damage (APEX) Warm Autoimmune Hemolytic Anemia (ENERGY) EU Localized Prostate Cancer (ATLAS) Psoriasis (ICONIC-ADVANCE 1&2 Update) Localized Prostate Cancer (ATLAS) Ulcerative Colitis (DUET-UC) P US ICOTYDE (icotrokinra) US CAPLYTA (lumateperone) US ERLEADA (apalutamide) ICOTYDE (icotrokinra) ERLEADA (apalutamide) JNJ-4804 Co-antibody Therapy EU Psoriasis (ICONIC) Bipolar Mania EU High Risk Prostate Cancer (PROTEUS) Psoriasis (ICONIC-ASCEND) High Risk Prostate Cancer (PROTEUS) Crohn's Disease (DUET-CD) AKEEGA (niraparib/abiraterone) US bleximenib icotrokinra TALVEY (talquetamab) JNJ-4804 Co-antibody Therapy EU M1 Metastatic Castration- Sensitive Prostate Cancer (AMPLITUDE) Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1) Psoriatic Arthritis (ICONIC-PsA) Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3) Psoriatic Arthritis (AFFINITY) P US DARZALEX (daratumumab) P US TALVEY (talquetamab) ICOTYDE (icotrokinra) TECVAYLI (teclistamab) nipocalimab Frontline multiple myeloma transplant ineligible (CEPHEUS) P EU Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3) Psoriasis (ICONIC-TOTAL Update) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC- 9) Systemic Lupus Erythematosus (JASMINE) P US TECVAYLI (teclistamab) P US TECVAYLI (teclistamab) CAPLYTA (lumateperone) INLEXZO (gemcitabine intravesical delivery system) bleximenib EU Multiple Myeloma 1-3PLs (MajesTEC-3) P EU Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9) Bipolar Mania (ITI-007-452) High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5) Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1) TECVAYLI (teclistamab) TECVAYLI (teclistamab) nipocalimab JNJ-1887 sCD59 EU Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9) P EU Multiple Myeloma 1-3PLs (MajesTEC-3) Warm Autoimmune Hemolytic Anemia (ENERGY) Geographic Atrophy (PARASOL) US INLEXZO (gemcitabine intravesical delivery system) EU High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5) Johnson & Johnson Innovative Medicine Pipeline Key Events in 2026* 1. In order to be on key events clinical presentation, data must be presented at a major medical meeting. *This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of April 14, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. = Achieved -- 28 of 28 --